Spirita Oncology, LLC
2 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| E6201 Plus Dabrafenib for the Treatment of Metastatic Melanoma Central Nervous System Metastases (CNS) (NCT03332589) | Spirita Oncology, LLC | 2018-07-02 |
Track Spirita Oncology, LLC automatically
Every clearance here is in the API, with alerts when new ones post.